Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioInvent International AB ( (SE:BINV) ) has shared an announcement.
BioInvent reported new Phase 2a data for its anti-TNFR2 monoclonal antibody BI-1808 in advanced cutaneous T-cell lymphomas, showing a 40% objective response rate as a monotherapy and 50% in combination with Merck’s anti-PD-1 therapy KEYTRUDA. Responses included a complete remission in a Sézary syndrome patient lasting over two years, alongside robust immune activation marked by regulatory T-cell depletion, increased CD8+ T-cell infiltration and early immune-related skin flares, with an overall favorable safety profile.
The results, generated in a heavily pretreated population with mycosis fungoides and Sézary syndrome, suggest BI-1808 could offer a differentiated approach in a setting with few durable treatment options and support its continued development as both a single agent and in combination regimens. With the monotherapy arm advancing into dose optimization and BI-1808 already holding FDA Fast Track and Orphan Drug designations in T-cell lymphomas and European orphan status in CTCL, the program appears well positioned for expedited advancement, potentially strengthening BioInvent’s standing in the immuno-oncology landscape and offering new hope to patients and clinicians confronting relapsed CTCL.
The most recent analyst rating on (SE:BINV) stock is a Buy with a SEK90.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a Swedish biotechnology company focused on discovering and developing novel antibody-based immunotherapies for cancer. Listed on Nasdaq Stockholm, the company targets difficult-to-treat hematologic malignancies and solid tumors, with a particular emphasis on modulating the tumor microenvironment to enhance anti-tumor immune responses.
Average Trading Volume: 101,858
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.52B
For an in-depth examination of BINV stock, go to TipRanks’ Overview page.